Drug intelligence / Profile preview

SBP-801

Development stage: Preclinical
Lead developer: SML Biopharm
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SBP-801 is a preclinical-stage prophylactic mRNA vaccine developed by SML Biopharm for the prevention of COVID-19. The vaccine is constructed using SML Biopharm's proprietary mRNA/LNP (lipid nanoparticle) platform, which is designed to induce a robust immune response against the SARS-CoV-2 virus. The development of SBP-801 is supported by a South Korean government grants program and involves partnerships with the Korea Disease Control and Prevention Agency (KDCA) and EuBiologics. It is categorized within the company's 'Immune Response Based Therapeutics' pipeline.

Other names: SBP-801SBP801SBP 801

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SBP-801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBP-801.

Explore the full profile